Gilead Still Has Options After Indian Sovaldi Patent Refusal
This article was originally published in PharmAsia News
All is not lost for Gilead in its efforts to obtain a patent for Sovaldi in India. The company played down the latest rejection of its claims, noting that the main patent covering sofosbuvir is still pending with the Indian authorities. The company’s agreement with a group of Indian generic suppliers also remains unaltered.